SCHEMBL7401187

SCHEMBL7401187

NC(CCc1cc(O)c(C(c2cccc(NS(=O)(=O)c3ccccc3)c2)C2CC2)c(=O)o1)C(=O)N1CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.38
RORC P51449 1/20 0.34
MAP1LC3B Q9GZQ8 1/20 0.34
MAP1LC3A Q9H492 1/20 0.34
F2 P00734 5/20 0.34
TGFBR1 P36897 1/20 0.33
F10 P00742 4/20 0.33
PLG P00747 4/20 0.33
PLAU P00749 4/20 0.33
ST14 Q9Y5Y6 3/20 0.33
KDM5A P29375 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
AURKA O14965 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
DPP4 P27487 1/20 0.32
DPP7 Q9UHL4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7405582 0.90 CBLB (0.34) F2F10PLGPLAUST14
SCHEMBL7403251 0.88 SMYD3 (0.33)
SCHEMBL7404311 0.88 CBLB (0.33) F2F10PLGPLAUST14
SCHEMBL7401226 0.88 CBLB (0.36) F2F10PLGPLAUST14
SCHEMBL7402163 0.87 PARP1 (0.36) HTR6F2F10PLGPLAU
SCHEMBL7401181 0.87 HTR6 (0.39) HTR6MAP1LC3BMAP1LC3ATGFBR1ALDH1A1
SCHEMBL7401189 0.85 HTR6 (0.40) HTR6MAP1LC3BMAP1LC3ATGFBR1KDM5A
SCHEMBL7402046 0.85 MAP1LC3B (0.34) HTR6MAP1LC3BMAP1LC3AGAA
SCHEMBL7397200 0.84 MAP1LC3B (0.34) HTR6MAP1LC3BMAP1LC3AF2TGFBR1
SCHEMBL7402044 0.79 MAP1LC3B (0.33) HTR6MAP1LC3BMAP1LC3AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE 712 NORTH INC. 2021-08-12 US claimed
US-6169181-B1 HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS PHARMACIA & UPJOHN COMPANY 2001-01-02 US claimed
EP-0758327-A1 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1997-02-19 EP claimed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO claimed
US-6169181-B1 HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS PHARMACIA & UPJOHN COMPANY 2001-01-02 US disclosed
US-5852195-A Pyranone compounds useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1998-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE OPA1, OLA1, PITRM1 HTR6 3769/4885RORC 3280/4885MAP1LC3B 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.